TIGS, founded in 2017, is a non-profit research institute that aspires to develop solutions to challenges in human health and agriculture. TIGS is a unique initiative to support applications of cutting-edge science and technology in genetics and genomics to solve societal problems of the country. The most significant challenges that impede the achievement of health equity and nutrition security for all of India’s population require systematic evidence-based scientific advancements and technological solutions.

The U.S. Food and Drug Administration (FDA) has announced a new initiative aimed at accelerating the repurposing of already approved medicines to treat diseases with significant unmet medical needs, including rare disorders, neurodegenerative diseases, metabolic conditions, and substance use disorders.

OneSource Specialty Pharma Limited has announced a strong recovery in its fourth quarter performance for FY26, driven by growth across all major business segments and the commercial launch of semaglutide products in India. The company also reaffirmed its FY28 guidance of achieving nearly USD 400 million in organic revenue with around 40% EBITDA margin.

-- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, complement-driven diseases, is now a wholly owned subsidiary of Biogen.